Cardiovascular Revascularization Medicine最新文献

{"title":"Combined strategy of transcatheter edge-to-edge repair of mitral valve and percutaneous mechanical circulatory support device to treat high-risk patients with severe mitral regurgitation and cardiogenic shock","authors":"Mohsin S. Mughal, Divya Ratan Verma, Kapil Lotun, Mustafa Suppah, Sant Kumar, Thomas Waggoner, H. Kenith Fang, Satya Atmakuri, Hursh Naik","doi":"10.1016/j.carrev.2025.12.008","DOIUrl":"10.1016/j.carrev.2025.12.008","url":null,"abstract":"<div><h3>Background</h3><div>Acute mitral regurgitation (MR) associated with cardiogenic shock (CS) is a medical emergency with excessive in-hospital mortality. The vast majority of these patients are turned down for corrective surgery. The combined strategy of transcatheter edge-to-edge repair of mitral valves and percutaneous mechanical circulatory support devices to treat high-risk patients with severe mitral regurgitation and cardiogenic shock has not been evaluated in randomized controlled trials.</div></div><div><h3>Aims</h3><div>In this multicenter registry we aimed to assess the outcomes (all-cause mortality, other important secondary outcomes included freedom from 30-day cardiac death or cardiac readmission, 30-day all-cause mortality, 30-day cardiovascular mortality, and 30-day MACE events) of the combined strategy of Transcatheter Edge-to-Edge Repair of Mitral Valve and Percutaneous Mechanical Circulatory Support Device to Treat High-Risk Patients with Severe Mitral Regurgitation and Cardiogenic Shock.</div></div><div><h3>Methods</h3><div>This multicenter registry retrospectively evaluated all consecutive patients who presented with severe MR, had persistent cardiogenic shock (CS) despite appropriate therapy (including mechanical circulatory support [MCS]), were turned down for surgery due to operative risk from acuity at presentation, and were considered for TEER by a heart team.</div></div><div><h3>Results</h3><div>Twenty-one consecutive patients with severe acute or acute-on-chronic MR (anatomy suitable for M-TEER) and CS who were undergoing TEER after surgical turndown were included. Mean age was 63 years (SD ± 12.4), 71 % males, mean Society of Thoracic Surgeons Score predicted risk of mortality (STS-PROM) was 20.1 ± 19.2 % (range: 3.1 to 82), 71 % required mechanical ventilation, 52 % had pulmonary edema, 48 % had index acute myocardial infarction (AMI), 19 % required dialysis, 100 % had Impella™ in place. Immediate procedural outcomes included 100 % technical success, MR grade 1.2+ (mild, <em>p</em> < 0.001), and no events for device-device interaction were observed. The primary outcome of in-hospital all-cause mortality was 4.7 % (1 death from multiorgan failure). All-cause mortality at 30 days was 14 %, and three patients died. The procedural success rate was 81 %, with one readmission for DVT that was treated with oral anticoagulation, and none of the patients required mitral valve reintervention at 30-day follow up. Echocardiography at 30 days revealed an MR grade of ≤2+ (mild or moderate) in 94 %, and mean LVEF improved from baseline to 30 days (24.3 ± 11.3 % vs 30.5 ± 14 % respectively) (<em>p</em> = 0.001).</div></div><div><h3>Conclusions</h3><div>Patients with severe mitral regurgitation and cardiogenic shock, who are at high risk for surgery, were treated with a combined approach of percutaneous mechanical circulatory support and transcatheter edge-to-edge repair of MV. We found this approach safe and it effectively ","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"89 ","pages":"Pages 76-84"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145783434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Saline optical coherence tomography in percutaneous coronary intervention: Practical considerations and technical guidance","authors":"Bernard Wong,&nbsp;Bharat Khialani,&nbsp;James Xu,&nbsp;Cuneyt Ada,&nbsp;Eugene B. Wu,&nbsp;Scott Harding","doi":"10.1016/j.carrev.2026.04.024","DOIUrl":"10.1016/j.carrev.2026.04.024","url":null,"abstract":"<div><div>Optical coherence tomography (OCT) is a high-resolution intravascular imaging modality that provides detailed assessment of plaque morphology, stent optimization and procedural complications during percutaneous coronary intervention (PCI). Conventional OCT requires injection of contrast for blood clearance during image acquisition, which can increase the risk of contrast-induced nephropathy particularly in patients with renal dysfunction. Saline-based OCT has emerged as an alternative strategy to reduce contrast exposure, with available data supporting its safety and diagnostic quality in a substantial proportion of cases. However, its adoption remains limited, largely due to technical challenges in achieving adequate blood clearance with saline. This review article aims to outline the differences in physical properties between saline and contrast, highlights practical technical considerations for saline-based OCT acquisition, and proposes strategies for workflow integration in contemporary PCI practice.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"89 ","pages":"Pages 91-96"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147844603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: FFR/iFR discordance in AS – More a physiologic than anatomic cause?","authors":"Morton J. Kern,&nbsp;Arnold H. Seto","doi":"10.1016/j.carrev.2026.05.012","DOIUrl":"10.1016/j.carrev.2026.05.012","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"89 ","pages":"Pages 59-60"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148151684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of frailty on outcomes following percutaneous coronary intervention for acute myocardial infarction: A propensity-score matched analysis of 45,362 pairs","authors":"Hritvik Jain,&nbsp;Nandan Patel,&nbsp;Mushood Ahmed,&nbsp;Omar Baqal,&nbsp;Amir Lotfi,&nbsp;John A. Dodson,&nbsp;Andrew Goldsweig","doi":"10.1016/j.carrev.2026.01.009","DOIUrl":"10.1016/j.carrev.2026.01.009","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"89 ","pages":"Pages 48-51"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146041737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of clinical outcomes of acute myocardial infarction patients complicated with cardiogenic shock treated with intra-aortic balloon pump versus microaxial flow pump","authors":"Beni Rai Verma,&nbsp;Abhinav Sood,&nbsp;Kalyan Chitturi,&nbsp;Abdullah Al Qaraghuli,&nbsp;Dan Haberman,&nbsp;Cheng Zhang,&nbsp;Sevket T. Ozturk,&nbsp;Vaishnavi Sawant,&nbsp;Yama Thakkar,&nbsp;Jason Galo,&nbsp;Waiel Abusnina,&nbsp;Itsik Ben-Dor,&nbsp;Brian C. Case,&nbsp;Hayder Hashim,&nbsp;Ron Waksman","doi":"10.1016/j.carrev.2025.12.023","DOIUrl":"10.1016/j.carrev.2025.12.023","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;The Danish-German (DanGer) Shock trial demonstrated that the use of a microaxial flow pump (Impella) reduced mortality compared to medical management in patients with acute ST elevation myocardial infarction complicated with cardiogenic shock (STEMI-CS). However, patients in the control arm of the DanGer Shock trial were not treated with an intra-aortic balloon pump (IABP), and data directly comparing Impella to IABP in this population is limited.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We identified STEMI-CS patients treated with percutaneous coronary intervention (PCI) and IABP at our institution between January 1, 2013, and February 20, 2025. These patients were screened according to the selection criteria of the DanGer Shock trial and were compared to the Impella MCS device 2.5 or CP and standard-of-medical-care (SoMC) arms of the DanGer Shock trial.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Our cohort included 102 STEMI-CS patients treated with IABP. Compared to Impella CP patients from the DanGer Shock trial, IABP patients had significantly higher rates of hypertension, diabetes mellitus, heart failure, and SCAI stage E cardiogenic shock, but significantly lower rates of mechanical ventilation, vasopressor, and inotrope use. At 180 days, IABP patients had similar all-cause mortality compared to Impella CP patients (35.9 % vs. 45.8 %, &lt;em&gt;p&lt;/em&gt; = 0.06), and lower rates of major bleeding (6 % vs. 39 %, &lt;em&gt;p&lt;/em&gt; &lt; 0.001) and renal replacement therapy (8 % vs. 75 %, p &lt; 0.001). Additionally, IABP patients had lower mortality compared to SoMC patients (35.9 % vs. 58.5 %, &lt;em&gt;p&lt;/em&gt; = 0.0004).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;These findings support the hypothesis that STEMI-CS patients treated with IABP have comparable 180-day mortality to those treated with Impella CP and lower mortality than those receiving standard medical care. STEMI-CS cohort is heterogenous and IABP use may be beneficial in certain patients. Well-designed randomized trials comparing Impella CP and IABP in this patient population are warranted to inform clinical decision-making.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Condensed abstract&lt;/h3&gt;&lt;div&gt;Acute ST elevation myocardial infarction complicated with cardiogenic shock (STEMI-CS) portends a high mortality risk. New American guidelines now recommend a peripherally inserted left ventricular assist device, such as Impella, as a Class II indication for the management of STEMI-CS patients. Further, guidelines now give intra-aortic balloon pump (IABP) as a class III indication for these patients. However, there is a need of direct head-to-head comparison of these two mechanical support modalities in this specific subset of patients. In this analysis, we identified STEMI-CS patients treated with IABP at our institution and compared them to the Impella CP cohort from the DanGer Shock trial. We found that both modalities had similar mortality rates, and IABP has lower mortality rates when compared to standard medica","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"89 ","pages":"Pages 42-47"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145994657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tirzepatide therapy reduces subclinical leaflet thrombosis and paravalvular leak after transcatheter aortic valve replacement in obese patients: The TAVR-MET trial","authors":"A.M. Thirugnanam,&nbsp;Chandrakanth,&nbsp;Pruthvi","doi":"10.1016/j.carrev.2026.03.011","DOIUrl":"10.1016/j.carrev.2026.03.011","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Obesity is increasingly recognized as a critical modifier of outcomes following transcatheter aortic valve replacement (TAVR), predisposing patients to subclinical leaflet thrombosis (SLT), hypo-attenuated leaflet thickening (HALT), and paravalvular leak (PVL). Metabolic inflammation, endothelial dysfunction, and pro-thrombotic states associated with obesity contribute to impaired bioprosthetic valve healing. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated robust metabolic, anti-inflammatory, and vascular protective effects. However, its impact on post-TAVR valve performance has not been previously evaluated.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Objectives&lt;/h3&gt;&lt;div&gt;To determine whether tirzepatide therapy initiated before TAVR and continued post-procedure reduces the incidence of HALT and PVL in obese patients undergoing TAVR.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;TAVR-MET was a prospective, randomized, open-label, multicenter trial enrolling obese patients (BMI ≥ 30 kg/m&lt;sup&gt;2&lt;/sup&gt;) undergoing transfemoral TAVR. Patients were randomized to tirzepatide therapy or standard care. The primary endpoint was HALT incidence at 6 months assessed by 4D-CT or transesophageal echocardiography (TEE). Secondary endpoints included PVL severity, major adverse valve events (MAVE), inflammatory biomarker changes, weight reduction, and bleeding outcomes.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;Among 260 randomized patients, tirzepatide therapy significantly reduced HALT incidence (8.4% vs 21.6%, &lt;em&gt;p&lt;/em&gt; = 0.002) and ≥ mild PVL (10.7% vs 25.3%, &lt;em&gt;p&lt;/em&gt; = 0.006) at 6 months. Tirzepatide was associated with marked reductions in CRP and body weight without an increase in major bleeding. Multivariable analysis identified tirzepatide use, CRP reduction &gt;30%, and BMI &lt;32 kg/m&lt;sup&gt;2&lt;/sup&gt; at follow-up as independent predictors of HALT absence.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;Metabolic modulation with tirzepatide significantly improves post-TAVR valve healing and hemodynamics in obese patients. These findings introduce a novel cardio-metabolic strategy to reduce structural valve complications following TAVR.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Trial summary: TAVR-MET study&lt;/h3&gt;&lt;div&gt;The &lt;strong&gt;TAVR-MET trial&lt;/strong&gt; was a prospective, randomized, multicenter study designed to evaluate whether metabolic modulation with &lt;strong&gt;tirzepatide&lt;/strong&gt;, a dual GIP/GLP-1 receptor agonist, could improve bioprosthetic valve outcomes following &lt;strong&gt;transcatheter aortic valve replacement (TAVR)&lt;/strong&gt; in obese patients.&lt;/div&gt;&lt;div&gt;Obesity is increasingly recognized as a key determinant of post-TAVR complications, particularly &lt;strong&gt;subclinical leaflet thrombosis (HALT)&lt;/strong&gt; and &lt;strong&gt;paravalvular leak (PVL)&lt;/strong&gt;, driven by chronic inflammation, endothelial dysfunction, and a prothrombotic state. Tirzepatide has demonstrated potent weight-reducing, anti-inflamma","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"89 ","pages":"Pages 87-90"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147718376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: That's why it's called “hardening of the arteries”. The challenge of PCI in calcified coronary arteries","authors":"Michael Ragosta","doi":"10.1016/j.carrev.2026.07.001","DOIUrl":"10.1016/j.carrev.2026.07.001","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"89 ","pages":"Pages 66-67"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148382903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends of myocardial infarction in young patients","authors":"Mahmoud Khalil,&nbsp;Dharmindra Dulal,&nbsp;Ahmed Younes,&nbsp;Hossam Albeyoumi,&nbsp;Ahmed Maraey,&nbsp;Ahmed M. Elzanaty,&nbsp;Emmanouil S. Brilakis,&nbsp;Khaldoon Alaswad,&nbsp;Mir B. Basir,&nbsp;Michael Megaly","doi":"10.1016/j.carrev.2026.01.015","DOIUrl":"10.1016/j.carrev.2026.01.015","url":null,"abstract":"<div><h3>Aim</h3><div>While the overall incidence and mortality of ST-elevation myocardial infarction (STEMI) have declined, younger adults 18–40 years of age have experienced a different trend. We examined STEMI incidence, mortality, and mechanical circulatory support (MCS) utilization in young patients from 2004 to 2023 using the TriNetX Research Network database.</div></div><div><h3>Methods</h3><div>We conducted an analysis of a cohort of 34,888, 311 patients aged 18–40 years between January 1, 2004, and December 31, 2023, using TriNetX Research Network database. Linear regression analysis was used to calculate the incidence rate of STEMI. The incidence of major cardiovascular risk factors including diabetes mellitus, hypertension, nicotine dependence, obesity, cocaine use disorder, and stimulant use disorder, were evaluated in the same cohort over the same period. Mortality and MCS utilization were examined from 2010 onward.</div></div><div><h3>Results</h3><div>STEMI incidence rate increased significantly from 2004 to 2023 (1.59/100,000 cases/person-year; <em>p</em> &lt; 0.0001). Mortality incidence rate increased annually by 108/100,000 (p &lt; 0.0001), while MCS utilization rose by 38.8/100,000 (p &lt; 0.0001). Cardiovascular risk factors also increased significantly.</div></div><div><h3>Conclusion</h3><div>STEMI incidence, mortality, and MCS utilization among young adults have increased between 2004 and 2023, with a steeper uptrend observed post-COVID. Further research is needed to identify effective prevention and treatment strategies for STEMI in young adults, particularly in the post-COVID era.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"89 ","pages":"Pages 23-29"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148776219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durability of balloon-expandable and self-expandable transcatheter aortic valves in patients with a large aortic annulus","authors":"Kenichi Ishizu,&nbsp;Shinichi Shirai,&nbsp;Masaomi Hayashi,&nbsp;Toru Morofuji,&nbsp;Akihiro Isotani,&nbsp;Nobuhisa Ohno,&nbsp;Shinichi Kakumoto,&nbsp;Kenji Ando,&nbsp;Masanori Yamamoto,&nbsp;Hirofumi Hioki,&nbsp;Tetsuro Shimura,&nbsp;Fumiaki Yashima,&nbsp;Toru Naganuma,&nbsp;Masahiko Asami,&nbsp;Yohei Ohno,&nbsp;Yusuke Watanabe,&nbsp;Futoshi Yamanaka,&nbsp;Gaku Nakazawa,&nbsp;Masahiko Noguchi,&nbsp;Masaki Izumo,&nbsp;Kentaro Hayashida","doi":"10.1016/j.carrev.2025.12.006","DOIUrl":"10.1016/j.carrev.2025.12.006","url":null,"abstract":"<div><h3>Background</h3><div>Limited evidence has been available on the long-term prognosis and valve durability of balloon-expandable transcatheter heart valve (BE-THV) and self-expandable transcatheter heart valve (SE-THV) in patients with large aortic annulus (LAA).</div></div><div><h3>Objectives</h3><div>To compare the long-term outcomes between the BE-THV and SE-THV.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 1054 patients undergoing transfemoral transcatheter aortic valve implantation (TAVI) for tricuspid aortic valve stenosis with LAA, defined as an annulus area &gt; 430 mm², using either a BE-THV (SAPIEN 3, Edwards Life Sciences) or SE-THV (Evolut R/PRO, Medtronic). The 7-year cumulative incidences of all-cause mortality and bioprosthetic valve failure (BVF) were evaluated in the overall cohort and the propensity score (PS)-matched cohort.</div></div><div><h3>Results</h3><div>Among the 1054 patients with LAA, 829 (78.7 %) received a BE-THV. The PS-matched population resulted in 218 pairs. The cumulative incidence of all-cause mortality 7 years after TAVI was comparable between the BE-THV and SE-THV groups in the overall cohort (58.6 % vs. 67.6 %, log-rank <em>P</em> = 0.848) and the PS-matched cohort (53.2 % vs. 69.9 %, log-rank <em>P</em> = 0.173). In the overall cohort, the BE-THV group demonstrated a lower exposure-adjusted BVF rate as compared with the SE-THV, although the difference was not significant (6.1 vs. 9.6 events per 1000 patient-years, <em>P</em> = 0.258). This trend became pronounced after PS matching (3.3 vs. 9.9 events per 1000 patient-years, <em>P</em> = 0.017), which was also confirmed by Gray's test (<em>P</em> = 0.032).</div></div><div><h3>Conclusions</h3><div>In the current analysis focusing on patients with LAA, the BE-THV and SE-THV groups had a comparable long-term prognosis, but the BE-THV group had a lower BVF rate than did the SE-THV group.</div></div><div><h3>Clinical trial registration</h3><div>UMIN000020423</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"89 ","pages":"Pages 68-75"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145758131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to publication: Percutaneous micro-axial flow pump use during non-emergent high-risk PCI","authors":"Jason R. Wollmuth,&nbsp;Cristina Aurigemma,&nbsp;Vasileios F. Panoulas,&nbsp;Amir Kaki","doi":"10.1016/j.carrev.2026.01.017","DOIUrl":"10.1016/j.carrev.2026.01.017","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"89 ","pages":"Pages 99-100"},"PeriodicalIF":2.3,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146229251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}